From the Department of Plastic and Reconstructive Surgery, University of Ulsan, College of Medicine, Seoul Asan Medical Center.
SUI Plastic Surgery.
Plast Reconstr Surg. 2024 Feb 1;153(2):337-343. doi: 10.1097/PRS.0000000000010528. Epub 2023 Apr 4.
Botulinum neurotoxin type A (BTX-A) to the masseter muscle is a useful tool for the aesthetic narrowing of the width of the lower face. The administration of BTX-A to visible parotid glands is also effective to reduce lower facial width. However, no studies have quantitatively analyzed the effect of BTX-A on the parotid glands.
The purpose of this study was to confirm the impact of BTX-A injection on the parotid gland and to suggest the effective dosage of BTX-A in facial slimming. This study was conducted by selecting patients who desired facial slimming from among patients who required surgery for a facial bone fracture. Patients undergoing BTX-A injection were randomized to high-dose, low-dose, and placebo groups, and different doses of BTX-A for each group were injected into both parotid glands during facial bone surgery.
A total of 30 patients were enrolled in this study. Ten patients in the high-dose group, eight in the low-dose group, and nine in the control group completed the clinical trial. There were significant changes in both the high- and low-dose groups compared with the control group ( P < 0.001, P < 0.001), and in interaction of time and group ( P < 0.001). Volume recovery after 3 months was found in 7.6% in the high-dose group and in 4.8% in the low-dose group.
BTX-A injection into parotid glands can be an effective treatment option in managing salivary gland enlargement for lower face contouring.
CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, II.
将肉毒毒素 A（BTX-A）注射至咬肌是一种缩小下面部宽度的有效方法。将 BTX-A 注射至可见的腮腺也可有效减小下面部的宽度。然而，目前尚无研究对 BTX-A 对腮腺的作用进行定量分析。
本研究旨在确认 BTX-A 注射对面部宽度的影响，并为面部瘦身提出 BTX-A 的有效剂量。本研究通过从需要面部骨折手术的患者中选择需要面部瘦身的患者进行，将接受 BTX-A 注射的患者随机分为高剂量组、低剂量组和安慰剂组，每组患者均在面部骨折手术期间将不同剂量的 BTX-A 注射至双侧腮腺。
本研究共纳入 30 例患者。其中高剂量组 10 例、低剂量组 8 例和对照组 9 例完成了临床试验。与对照组相比，高剂量组和低剂量组均有显著变化（P<0.001，P<0.001），且时间和组间存在交互作用（P<0.001）。高剂量组和低剂量组的腮腺体积在 3 个月后分别有 7.6%和 4.8%的恢复。
将 BTX-A 注射至腮腺可能是一种治疗下面部轮廓整形中唾液腺肿大的有效方法。
临床问题/证据水平：治疗，II 级。
